All News
NSAID Safety with COVID-19 Infection
NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.
Read Article
Insurers Bet Big on Bribing Patients
Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division. They could receive a $500 debit card from Cigna, with just one string attached: they would have to switch to a different medication, one preferred by the insurer.
Read Article
RheumNow Podcast – Falling or Falling in Love?
Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.
Read Article
Drug Monitoring Ineffective with Infliximab Treatment
The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.
Read Article
RheumNow Podcast – Uppers and Downers
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Seven Year Delay in Diagnosing Spondyloarthritis
A large patient cohort study suggests that the mean diagnostic delay (DD) in European axial spondyloarthritis (axSpA) patients is 7.4 years, moreso in women and younger patients.
Read Article
Golimumab Effective in non-radiographic Axial Spondyloarthritis
The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA). After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein GLM pa
Read Article
Diagnostic Delay in Spondyloarthritis
Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.
Read Article
BSRBR: Demyelinating Disease Following Anti-TNFα Therapy
Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally incrased by taking TNFi therapy.
Read Article
Broadalumab Efficacy in Axial Spondyloarthritis
Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).
Read Article
RheumNow Podcast – Combination Biologics
Dr. Jack Cush serves up this week's news and articles from RheumNow.com.
Read Article
IL-23 Targeting for Enthesitis in Psoriatic Arthritis
Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.
Read Article
Low Risk of Malignancy with Secukinumab
Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).
Read Article
DMARD Dropouts During COVID-19
A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.
Read Article
RheumNow Podcast – Mistakes with Steroids
Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
Read Article
RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)
Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
Read Article
Inflammatory Conditions Up the Risk of Premature Myocardial Infarction
The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Read Article
HLA B27 Iritis - RNL 2021 Highlights
The Spondyloarthritis Advances pod presented during the RheumNow Live 2021 conference featured three speakers, including an excellent lecture by Dr. Robert Wang, ophthalmology, on HLA B27 iritis and practical tips for rheumatologists.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links: